Immunological cross-reactivity against a drug mutated HIV-1 protease epitope after DNA multi-CTL epitope construct immunization

被引:5
作者
Boberg, A
Sjöstrand, D
Rollman, E
Hinkula, J
Zuber, B
Wahren, B
机构
[1] Karolinska Inst, Swedish Inst Infect Dis Control, S-17182 Solna, Sweden
[2] Karolinska Inst, Microbiol & Tumorbiol Ctr, Stockholm, Sweden
[3] Karolinska Inst, Dept Neurosci, Stockholm, Sweden
[4] Mabtech AB, Stockholm, Sweden
关键词
HIV-1; drug resistance; DNA multi-CTL epitope construct; cross reactivity;
D O I
10.1016/j.vaccine.2005.08.019
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Epitopes in HIV polymerase were analyzed by peptide binding to human leukocyte antigen (HLA) A0201 molecules, the most frequent HLA class in the Caucasian population. We found that HIV-1 protease peptides representing both the wild type and anticipated drug resistance variants of the sequence bound well to HLA-A0201. We also found that wild type as well as a double mutated variant of the epitope was strongly immunogenic in HLA-A0201 transgenic mice, either as individual peptides or encoded in DNA multi-CTL epitope constructs. Immunological cross-reactivity between different variants of the peptide could be seen, suggesting that it may be possible to induce a broad immune response by immunizing with drug resistance-mutated epitopes. This may be of advantage for HIV-1 infected patients since such a response may cause a better outcome of an anti-retroviral drug therapy. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4527 / 4530
页数:4
相关论文
共 18 条
[1]   Minor nef gene alterations after human HIV-DNA immunisation [J].
Aleman, S ;
Leitner, T ;
Liu, MA ;
Wahren, B .
AIDS, 2004, 18 (05) :817-819
[2]   Rates of transmission of antiretroviral drug resistant strains of HIV-1 [J].
Ammaranond, P ;
Cunningham, P ;
Oelrichs, R ;
Suzuki, K ;
Harris, C ;
Leas, L ;
Grulich, A ;
Cooper, DA ;
Kelleher, AD .
JOURNAL OF CLINICAL VIROLOGY, 2003, 26 (02) :153-161
[3]  
Firat H, 2001, EUR J IMMUNOL, V31, P3064, DOI 10.1002/1521-4141(2001010)31:10<3064::AID-IMMU3064>3.0.CO
[4]  
2-L
[5]  
Johnson Victoria A, 2003, Top HIV Med, V11, P215
[6]   Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines [J].
Livingston, BD ;
Newman, M ;
Crimi, C ;
McKinney, D ;
Chesnut, R ;
Sette, A .
VACCINE, 2001, 19 (32) :4652-4660
[7]   EMPTY MHC CLASS-I MOLECULES COME OUT IN THE COLD [J].
LJUNGGREN, HG ;
STAM, NJ ;
OHLEN, C ;
NEEFJES, JJ ;
HOGLUND, P ;
HEEMELS, MT ;
BASTIN, J ;
SCHUMACHER, TNM ;
TOWNSEND, A ;
KARRE, K ;
PLOEGH, HL .
NATURE, 1990, 346 (6283) :476-480
[8]   HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta 2 microglobulin (beta 2m) HLA-A2.1 monochain transgenic H-2D(b) beta 2m double knockout mice [J].
Pascolo, S ;
Bervas, N ;
Ure, JM ;
Smith, AG ;
Lemonnier, FA ;
Perarnau, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (12) :2043-2051
[9]   Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants [J].
Peter, K ;
Men, Y ;
Pantaleo, G ;
Gander, B ;
Corradin, G .
VACCINE, 2001, 19 (30) :4121-4129
[10]  
Pillay D, 2000, REV MED VIROL, V10, P231, DOI 10.1002/1099-1654(200007/08)10:4&lt